An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 1046-1052

  Gao, Yang ^a   Brimijoin, Stephen ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; COCAINE; COCAINE HYDROLASE; HYDROLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG OVERDOSE; HEART; HEMODYNAMIC MONITORING; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN ENGINEERING; RAT; TOXICOKINETICS; VAGUS REFLEX;

ANIMALS; CARDIOVASCULAR SYSTEM; COCAINE; ENZYME STABILITY; HEART RATE; HYDROLASES; MALE; PRESSORECEPTORS; PROTEIN ENGINEERING; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; VASOCONSTRICTOR AGENTS;

EID: 4243193692     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.068122     Document Type: Article

References (40)

1. Altamirano C and Lockridge O (1999) Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem Biol Interact 119-120:53-60.
2. Beckman KJ, Parker RB, Hariman RJ, Gallastegui JL, Javaid JI, and Bauman JL (1991) Hemodynamic and electrophysiological actions of cocaine: effects of sodium bicarbonate as an antidote in dogs. Circulation 83:1799-1807.
3. Benchimol A, Bartall H, and Desser KB (1978) Accelerated ventricular rhythm and cocaine abuse. Ann Int Med 88:519-520.
4. Benowitz N (1993) Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 72:3-12.
5. Bresler M, Rosser S, Basran A, and Bruce N (2000) Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl Environ Microbiol 66:904-908.
6. Brimijoin S, Shen M, and Sun H (2002) Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Anal Biochem 309:200-205.
7. Brown JH and Taylor P (2001) Muscarinic receptor agonists and antagonists, in Goodman & Gilman's Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE eds), McGraw-Hill, New York.
8. Carmona G, Jufer R, Goldberg S, Gorelick D, Greig N, Yu Q, Cone E, and Schindler C (2000) Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans. Drug Metab Dispos 28:367-371.
9. Carmona GN, Schindler CW, Shoaib M, Jufter R, Cone EJ, Goldberg SR, Greig NH, Yu QS, and Gorelick DA (1998) Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase. Exp Clin Psychopharmacol 6:274-279.
10. Carroll FI, Howell LL, and Kuhar MJ (1999) Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42:2721-2736.
11. Cascio C, Comite C, and Ghiara M (1982) The use of serum cholinesterase in severe phosphorus poisoning. Minerva Anestesiol 54:337-338.
12. Charney DS, Mihic J, and Harris RA (2001) Hypnotics and sedatives, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE eds) ed 10, pp 399-427, McGraw-Hill, New York.
13. Doctor BP (2003) Butyrylcholinesterase: its use for prophylaxis of organophosphate exposure, in Butyrylcholinesterase: Its Function and Inhibitors (Giacobini E ed.), pp 163-177, Martin Dunitz, London.
14. Ebert TJ (1990) Inhibition of sympathetic neural outflow during thiopental anesthesia in humans. Anesth Analg 71:319-326.
15. Ellman GL, Courtney KD, Andres VJ, and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
16. Gorelick D (1997) Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 48:159-165.
17. Hoffman R, Morasco R, and Goldfrank L (1996) Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. J Toxicol Clin Toxicol 34:259-266.
18. Inaba T, Stewart D, and Kalow W (1978) Metabolism of cocaine in man. Clin Pharmacol Ther 23:547-552.
19. Jain R, Jain M, Bachenheimer L, Visner M, Hamosh P, Tracy C, and Gillis R (1990) Factors determining whether cocaine will potentiate the cardiac effects of neurally released norepinephrine. J Pharmacol Exp Ther 252:147-153.
20. Krejci E, Thomine S, Boschetti N, Legay C, Sketelj J, and Massoulie J (1997) The mammalian gene of acetylcholinesterase-associated collagen. J Biol Chem 272: 22840-22847.
21. Landry DW, Zhao K, Yang GX-Q, Glickman M, and Georgiadis TM (1993) Antibody-catalyzed degradation of cocaine. Science (Wash DC) 259:1899-1901.
22. Lynch T, Mattes C, Singh A, Bradley R, Brady R, and Dretchen K (1997) Cocaine detoxification by human plasma butyrylcholinesterase. J Appl Pharmacol 145: 363-371.
23. Marzuk P, Tardiff K, Leon A, Hirsch C, Stajic M, Portera L, Hartwell N, and Iqbal M (1995) Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med 332:1753-1757.
24. Mattes C, Lynch T, Singh A, Bradley R, Kellaris P, Brady R, and Dretchen K (1997) Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol 145:372-380.
25. McKinney M (1998) Practical aspects of radioligand binding, in Current Protocols of Pharmacology, pp 1.3.1-1.3.33. John Wiley & Sons, New York.
26. Ostergaard D, Viby-Morgensen J, Hanel HK, and Skovgaard LT (1988) Half-life of plasma cholinesterase. Acta Anesth Scand 32:266-269.
27. Pancook JD, Pecht G, Ader M, Mosko M, Lockridge O, and Watkins JD (2003) Application of directed evolution technology to optimize the cocaine hydrolase activity of human butyrylcholinesterase. FASEB J 17:A565.
28. Pascual-Leone A, Dhuna A, Altafulla I, and Anderson DC (1990) Cocaine-induced seizures. Neurology 40:404-407.
29. Pitts DK, Udom CE, and Marwah J (1987) Cardiovascular effects of cocaine in anesthetized and conscious rats. Life Sci 40:1099-1111.
30. Przywara DA and Dambach GE (1989) Direct actions of cocaine on cardiac cellular electrical activity. Circ Res 65:185-192.
31. Rosenberg Y, Luo C, Ashani Y, Doctor BP, Fischer R, Wolfe G, and Saxena A (2002) Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase. Life Sci 72:125-134.
32. Stewart DJ, Inaba T, Tang BK, and Kalow W (1977) Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci 20:1557-1564.
33. Stovner J and Stadskleiv K (1976) Suxamethonium apnea terminated with commercial serum cholinesterase. Acta Anaesth Scand 20:211-215.
34. Sun H, El Yazal J, Brimijoin S, and Pang Y-P (2001) Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase: engineering effective butyrylcholinesterase mutants for cocaine detoxification. J Biol Chem 276:9330-9336.
35. Sun H, Pang Y-P, Lockridge O, and Brimijoin S (2002a) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 621:220-224.
36. Sun H, Shen ML, Pang Y-P, Lockridge O, and Brimijoin S (2002b) Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther 302:710-716.
37. Trendelenburg U (1966) Mechanisms of supersensitivity and subsensitivity to sympathomimetic amines. Pharmacol Rev 18:629-640.
38. Winbery S, Blaho K, Logan B, and Geraci S (1998) Multiple cocaine-induced seizures and corresponding cocaine and metabolite concentrations. Am J Emerg Med 16: 529-533.
39. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, and Lockridge O (1999) An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 55:83-91.
40. Zhan C, Zheng F, and Landry D (2003) Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J Am Chem Soc 125:2462-2474.